Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial-Reference-Cited by-同舟云学术

Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

Published:2018-09-13 Issue:2 Volume:129 Page:119-128
ISSN:0020-7454
Container-title:International Journal of Neuroscience
language:en
Short-container-title:International Journal of Neuroscience

Author:

Markovà Jolana¹,Essner Ute²,Akmaz Bülent³,Marinelli Marcella⁴,Trompke Christiane⁵,Lentschat Arnd⁵,Vila Carlos⁶

Affiliation:

1. Neurology Department, Thomayer's Hospital, Praha, Czechia;

2. O. Meany Consultancy GmbH, Hamburg, Germany;

3. Market Access Manager, Almirall Hermal GmbH, Reinbek, Germany;

4. Clinical Statistics, Almirall S.A., Barcelona, Spain;

5. International Clinical Trial Managers, Almirall Hermal GmbH, Reinbek, Germany;

6. Neurology Medical Manager, Global Medical Affairs, Almirall S.A., Barcelona, Spain

Funder

Almirall Hermal GmbH and Almirall S.A.

Publisher

Informa UK Limited

Subject

General Medicine,General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/00207454.2018.1481066

Reference22 articles.

1. Prevalence and treatment of spasticity reported by multiple sclerosis patients

2. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice

3. Natural History of Multiple Sclerosis Symptoms

4. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines

5. Spasticity in multiple sclerosis: Associations with impairments and overall quality of life

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of the Bayesian network theory in clinical trial data: Severity shift in spasticity numeric rating scale in patients with multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-03

2. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures;Neurodegenerative Disease Management;2024-02-06

3. Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials;BMJ Open;2024-01

4. Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials;Current Neuropharmacology;2023-12

5. Therapeutic use of medical Cannabis in neurological diseases: a clinical update;Journal of Neural Transmission;2023-11-28